Kynmobi (Apomorphine Hydrochloride Hemihydrate)

Apomorphine is a non‑selective dopamine agonist that stimulates D1 and D2 receptors in the brain. By directly activating these receptors, it compensates for low dopamine levels, improving the signaling pathways that control movement.

The dose of Kynmobi is individualized. A qualified prescriber determines the appropriate starting dose and any subsequent titration based on the patient’s clinical response and tolerance.

Safety data for apomorphine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a healthcare professional.

To request Kynmobi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kynmobi offers a rapid‑acting, sublingual route that can provide quicker relief compared with oral levodopa formulations. Unlike injectable apomorphine, the sublingual form avoids needles and may be more convenient for patients requiring frequent dosing.

Kynmobi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability.

Kynmobi is administered sublingually. The tablet or film is placed under the tongue and allowed to dissolve completely without swallowing, ensuring rapid absorption into the bloodstream.

Serious risks include severe hypotension, syncope, hallucinations, impulse control disorders, and rare allergic reactions. Patients should be monitored closely for these events, especially during dose initiation and titration.

Kynmobi is contraindicated in individuals with known hypersensitivity to apomorphine or any of its excipients, and in patients taking monoamine oxidase inhibitors. It should also be avoided in patients with uncontrolled cardiovascular disease or severe psychiatric conditions unless specifically directed by a physician.